0A6I Stock Chart & Stats
$0.38
$0.02(4.22%)
At close: 4:00 PM EDT
$0.38
$0.02(4.22%)
Day’s Range― - ―
52-Week Range$0.28 - $1.65
Previous CloseN/A
Volume1.25K
Average Volume (3M)5.13K
Market Cap
$7.75M
Enterprise Value-$3.19M
Total Cash (Recent Filing)$9.81M
Total Debt (Recent Filing)$302.59K
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Nov 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding21,765,478
10 Day Avg. Volume4,470
30 Day Avg. Volume5,125
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.52K
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$1.50Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Rebuilt EquityModest leverage and rebuilt equity provide a stronger capital structure than in earlier periods, reducing debt-related pressure and preserving some flexibility for clinical development. This is a meaningful cushion, although continued losses could erode it over time.
Focus On Rare Diseases And BiodefenseA pipeline aimed at rare diseases, unmet medical needs, and biodefense addresses areas where specialized treatments and preparedness products may have durable strategic relevance. This focus can support differentiated development opportunities if candidates achieve clinical and commercial validation.
Losses Largely Reflect Cash CostsThe close relationship between free cash flow and net loss offers clearer visibility into the company’s underlying cash economics, because reported losses are not being materially distorted by non-cash accounting items. That transparency can aid financing and operating decisions.
Bears Say
Pre-revenue Model With Widening LossesThe absence of meaningful revenue leaves the company without an established commercial earnings base, while widening losses show that spending has not yet translated into operating scale. Until products generate revenue, profitability remains dependent on successful development and future financing.
Persistent Cash Burn And Funding DependenceSustained negative operating cash flow requires continuing access to external capital, increasing financing risk and potentially diluting shareholders. The expanded ATM program and prior stock sales demonstrate that funding operations remains an ongoing requirement rather than a temporary need.
Pipeline Setback And Delisting PressureEnding a Phase 3 program after a futility recommendation removes an important potential value driver and narrows the development base. Nasdaq bid-price noncompliance adds a separate listing risk that can complicate financing, investor access, and strategic execution.
Soligenix News
0A6I FAQ
What was Soligenix’s price range in the past 12 months?
Soligenix lowest share price was $0.28 and its highest was $1.65 in the past 12 months.
What is Soligenix’s market cap?
Soligenix’s market cap is $7.75M.
When is Soligenix’s upcoming earnings report date?
Soligenix’s upcoming earnings report date is Nov 06, 2026 which is in 5 days.
How were Soligenix’s earnings last quarter?
Soligenix released its earnings results on Aug 07, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.155 by $0.035.
Is Soligenix overvalued?
According to Wall Street analysts Soligenix’s price is currently Undervalued.
Does Soligenix pay dividends?
Soligenix does not currently pay dividends.
What is Soligenix’s EPS estimate?
Soligenix’s EPS estimate is -0.11.
How many shares outstanding does Soligenix have?
Soligenix has 21,765,478 shares outstanding.
What happened to Soligenix’s price movement after its last earnings report?
Soligenix reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.155. Following the earnings report the stock price went up 2.902%.
Which hedge fund is a major shareholder of Soligenix?
Currently, no hedge funds are holding shares in GB:0A6I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
0A6I Stock 12 Month Forecast
Average Price Target
$1.50
▲(294.74% Upside)